SCHEMBL2406396

SCHEMBL2406396

Cc1ccc(OB(c2ccc(C)c(Cl)c2)C(CN)c2ccccc2)cc1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DRD2 P14416 1/20 0.38
▸ DRD4 P21917 1/20 0.38
▸ DRD3 P35462 1/20 0.38
▸ POLB P06746 1/20 0.34
▸ SLC6A4 P31645 2/20 0.33
▸ SCN4A P35499 3/20 0.33
▸ SMN1; SMN2 Q16637 3/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ SLC6A2 P23975 1/20 0.33
▸ SLC6A3 Q01959 1/20 0.33
▸ NOS2 P35228 1/20 0.33
▸ LMNA P02545 3/20 0.32
▸ ALDH1A1 P00352 3/20 0.32
▸ MAPT P10636 3/20 0.32
▸ GAA P10253 2/20 0.32
▸ HTR1E P28566 1/20 0.32
▸ S1PR3 Q99500 1/20 0.32
▸ AGTR1 P30556 1/20 0.32
▸ CHRNB2 P17787 1/20 0.32
▸ CHRNA4 P43681 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2406421 0.84 DRD2 (0.34) DRD2DRD4DRD3POLBSLC6A4
SCHEMBL1555332 0.80 NOS2 (0.38) POLBSLC6A4SCN4ASMN1; SMN2SLC6A2
SCHEMBL1555334 0.76 NOS2 (0.43) DRD2DRD4DRD3POLBSLC6A4
SCHEMBL2405725 0.74 DRD2 (0.39) DRD2DRD4DRD3POLBSLC6A4
SCHEMBL1555103 0.72 SCN4A (0.48) DRD2DRD4DRD3POLBSCN4A
SCHEMBL12270797 0.72 NOS2 (0.47) POLBSLC6A4SCN4ASMN1; SMN2SLC6A2
SCHEMBL2398467 0.71 ALDH1A1 (0.37) DRD2DRD4DRD3POLBSLC6A4
SCHEMBL5370770 0.70 DRD2 (0.37) DRD2DRD4DRD3POLBSLC6A4
SCHEMBL5373601 0.70 DRD2 (0.37) DRD2DRD4DRD3POLBSLC6A4
SCHEMBL5370766 0.70 DRD2 (0.37) DRD2DRD4DRD3POLBSLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853424-B2 Protein cross-linking inhibitor JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2014-10-07 — — US disclosed
US-20110212919-A1 PROTEIN CROSS-LINKING INHIBITOR JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2011-09-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110212919-A1 PROTEIN CROSS-LINKING INHIBITOR BAZ2B, PRMT1, BRIX1 DRD2 3904/4885DRD4 4304/4885DRD3 3364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback